Lisa Rojkjaer insider trades: Viracta Therapeutics (VIRX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Lisa reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 27, 2023 | VIRX | ↓ Sell | 2,156 | $1.68 | $4K | Direct | Feb 28, 2023 (1d) |
| Nov 28, 2022 | VIRX | ↓ Sell | 2,116 | $2.72 | $6K | Direct | Nov 29, 2022 (1d) |
| Aug 26, 2022 | VIRX | ↓ Sell | 2,190 | $4.01 | $9K | Direct | Aug 29, 2022 (3d) |
| May 26, 2022 | VIRX | ↓ Sell | 2,154 | $1.90 | $4K | Direct | May 27, 2022 (1d) |
| Feb 28, 2022 | VIRX | ↓ Sell | 2,395 | $2.78 | $7K | Direct | Mar 1, 2022 (1d) |
| Nov 29, 2021 | VIRX | ↓ Sell | 4,541 | $4.81 | $22K | Direct | Nov 29, 2021 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Lisa Rojkjaer's insider trades
Lisa Rojkjaer is Chief Medical Officer at Viracta Therapeutics (VIRX). Since Nov 29, 2021, Lisa has reported no open-market purchases and 6 sales worth $51K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (9 filings), option exercises (7 filings), shares withheld for taxes (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VIRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.